JOURNAL OF HEALTH, MEDICAL RESEARCH AND INNOVATIONS

VOLUME: 01 ISSUE: 04 (2023)

P-ISSN : 3105-4749 E-ISSN: 3105-4757

https://www.jhmri.com

Research Article

ADVANCES IN VACCINE DEVELOPMENT: MRNA TECHNOLOGY BEYOND COVID-19

[1]*Dr. Hina Riaz*, [2]*Dr. Faisal Ahmed*, [3]*Dr. Laura J. Collins*,[4]*Dr. Kenji Tanaka*,

[1]*Department of Microbiology, University of the Punjab, Lahore, Pakistan*
Email: *hina.riaz@pu.edu.pk*

[2]*Department of Biological & Biomedical Sciences, Aga Khan University, Karachi, Pakistan*
Email: *faisal.ahmed@aku.edu.pk*

[3]*Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK*
Email: *laura.collins@ndm.ox.ac.uk*

[4]*Department of Vaccine Science, Graduate School of Medicine, The University of Tokyo, Japan*
Email: *kenji.tanaka@u-tokyo.ac.jp*

Abstract:

Messenger RNA (mRNA) platforms matured rapidly during the COVID-19 pandemic, establishing a new, programmable class of vaccines. Beyond SARS-CoV-2, the field has advanced along three fronts: (i) ***expanded indications****—with regulatory approval for adult* ***RSV*** *(mRNA-1345/mRESVIA) and late-stage programs in* ***seasonal influenza*** *and* ***cytomegalovirus (CMV)****; (ii)* ***therapeutic vaccination****, notably* ***personalized neoantigen vaccines*** *that augment immune checkpoint blockade; and (iii)* ***platform innovation****, including* ***self-amplifying RNA (saRNA)****,* ***circular RNA (circRNA)****, and improved* ***lipid nanoparticle (LNP)*** *delivery and thermostabilization. We review these advances, the clinical landscape, manufacturing and regulatory considerations, and outstanding challenges in durability, breadth, and equitable access. The trajectory suggests mRNA vaccines will anchor future routine immunization and oncology care, contingent on delivery and cost innovations.*

Keywords: *mRNA vaccines, RSV, influenza, CMV, cancer vaccines, lipid nanoparticles, self-amplifying RNA, circular RNA*

Introduction

The success of COVID-19 mRNA vaccines demonstrated that a software-like antigen design, coupled with scalable RNA synthesis and LNP delivery, can compress timelines from sequence to clinic. The post-pandemic period has validated this promise beyond COVID-19. In **May 2024**, the US FDA

approved **Moderna's RSV vaccine (mRNA-1345; mRESVIA)** for adults ≥60 years, and in **June 2025** expanded use to certain high-risk adults aged 18–59—marking the first non-COVID mRNA vaccine approval in the United States. Parallel phase-3 results for **mRNA influenza** (mRNA-1010) showed superiority versus a licensed comparator, strengthening the case for seasonal and combination mRNA respiratory vaccines. In **therapeutic oncology**, the **personalized neoantigen vaccine mRNA-4157 (V940)** improved recurrence-free and distant-metastasis-free survival when added to pembrolizumab in resected melanoma, catalyzing phase-3 development. At the platform level, **saRNA** promises dose-sparing and potentially improved stability, while **circRNA** aims for longer expression and reduced innate sensing; both require translational validation. Concurrently, **next-generation LNP chemistries** and formulation strategies target improved biodistribution, thermostability, and mucosal delivery.

Clinical Landscape Beyond COVID-19:

Respiratory Syncytial Virus (RSV):

Respiratory syncytial virus remains a leading cause of hospitalization in infants and severe lower respiratory tract disease among older adults. Until recently, no licensed RSV vaccines were available for adults. The approval of **mRNA-1345 (mRESVIA)** marks a historic milestone as the first mRNA vaccine licensed for a non-COVID pathogen. Initially approved in 2024 for adults aged **≥60 years**, regulatory expansion in **2025 extended coverage to high-risk adults aged 18–59**. Clinical trial data demonstrated **80–84% efficacy** against RSV-related lower respiratory tract disease, establishing strong immunogenicity across age subgroups. However, experts emphasize the need for **post-marketing surveillance** to assess durability of protection, rare adverse events, and effectiveness in immunocompromised patients. Ongoing studies will help determine whether booster strategies are necessary for sustained immunity. (Sources: Medical Letter, CIDRAP)

Seasonal Influenza:

Influenza viruses cause annual epidemics and occasional pandemics, but conventional egg-based vaccines have limitations: long production timelines, antigenic mismatch, and variable efficacy (often **30–60%**). Moderna's **mRNA-1010**, a quadrivalent seasonal flu vaccine, aims to overcome these issues through rapid design and manufacturing flexibility. In **phase-3 studies**, mRNA-1010 demonstrated a **~26–27% relative vaccine efficacy (rVE)** over a licensed comparator in adults ≥50 years. Importantly, this was achieved against circulating strains that had partially drifted from predictions, underscoring the adaptability of mRNA technology. These results support regulatory filings in the US and EU, with expectations that mRNA flu vaccines will soon be integrated into **combination COVID/flu booster programs**. The major challenges include ensuring **long-term durability**, addressing **immune imprinting** from prior flu exposures, and scaling production for seasonal demand. (Sources: Reuters, CIDRAP)

Cytomegalovirus (CMV):

Cytomegalovirus infection during pregnancy is the leading infectious cause of **congenital birth defects**, yet no licensed vaccine exists. Moderna's **mRNA-1647** (a six-antigen vaccine candidate) is currently in **phase-3 CMVictory trials**, targeting CMV-seronegative women of childbearing age. This represents a landmark effort to prevent **vertical transmission** of a latent herpesvirus. Phase-2 studies demonstrated **robust neutralizing antibody titers** and T-cell responses, suggesting strong potential for clinical protection. If successful, CMV vaccination could transform neonatal health by reducing the burden of **sensorineural hearing loss, cognitive disabilities, and developmental delays** linked to congenital CMV. Regulatory agencies are closely watching this program as a test case for **latent-virus vaccine development** using mRNA. The challenges include defining **correlates of protection**,

ensuring safety during pregnancy, and scaling production for a global maternal vaccine market. (Sources: ClinicalTrials.gov, Moderna Clinical Trials)

Oncology (Therapeutic Vaccines):

One of the most exciting frontiers for mRNA is **cancer immunotherapy**. Unlike prophylactic vaccines, therapeutic mRNA vaccines deliver **neoantigens**—tumor-specific mutated peptides—to train the immune system to recognize and destroy cancer cells. The **personalized cancer vaccine mRNA-4157 (V940)**, in combination with the checkpoint inhibitor **pembrolizumab**, showed **significant improvements in recurrence-free survival and distant metastasis-free survival** in resected melanoma patients (KEYNOTE-942 trial). These results represent the first randomized evidence that a personalized mRNA vaccine can improve outcomes in solid tumors. In addition, early trials in **pancreatic ductal adenocarcinoma (PDAC)** have demonstrated that RNA-based neoantigen vaccines can generate **durable $CD8^+$ T-cell memory responses**, which are crucial for long-term tumor control. The future of oncology vaccines depends on optimizing **bioinformatics pipelines for neoantigen selection**, reducing production timelines, and integrating them with other immunotherapies such as CAR-T and oncolytic viruses. (Sources: PubMed, Merck.com, Nature, clinical oncology reports)

HIV & Other Pathogens:

HIV has long eluded vaccine development due to its **genetic variability** and **immune evasion strategies**. However, mRNA platforms are providing new hope. In **phase-1 clinical trials**, germline-targeting mRNA immunogens successfully induced **precursor B cells** capable of developing into broadly neutralizing antibodies (bnAbs)—a crucial first step toward an effective HIV vaccine. These trials (e.g., IAVI G002/G003) represent the first demonstration that bnAb precursors can be reliably engaged in humans. Meanwhile, **Zika virus**, another major global health concern, has also advanced with mRNA platforms. Moderna's **mRNA-1893** has completed **phase-1** and entered **phase-2 trials**, showing strong neutralizing antibody responses with a favorable safety profile. These developments highlight the adaptability of mRNA in tackling pathogens for which traditional approaches have failed. Challenges remain in **achieving durable protection**, ensuring **cross-strain coverage**, and establishing **global access frameworks**. (Sources: IAVI, ClinicalTrials.gov, Nature)

Synthesis:

Taken together, the **clinical landscape of mRNA vaccines beyond COVID-19** is rapidly diversifying. RSV has become the first non-COVID approval, influenza is nearing licensure with superior phase-3 efficacy, CMV is breaking ground as the first latent-virus candidate, oncology applications are reshaping cancer treatment, and high-priority pathogens like HIV and Zika are entering early clinical validation. Each domain highlights both the **strengths of mRNA technology—speed, adaptability, immunogenicity—and the remaining challenges**, such as durability, regulatory clarity, and equitable global distribution.

Platform Innovations in mRNA Vaccine Technology:

Self-Amplifying RNA (saRNA):

Self-amplifying RNA (saRNA) vaccines are an extension of conventional mRNA technology that include not only the antigen-encoding sequence but also a **replicase gene**, often derived from alphaviruses such as **Sindbis virus, Semliki Forest virus, or Venezuelan equine encephalitis virus (VEEV)**. Once inside the cytoplasm, the replicase synthesizes multiple copies of the RNA, thereby amplifying antigen production far beyond the input dose.

Dose sparing: Early studies show saRNA vaccines can be effective at microgram or even sub-microgram doses, compared to tens of micrograms for conventional mRNA. This makes them attractive for **pandemic stockpiling** and for use in **low-resource settings**, since less raw material is needed.

Stability: Some formulations of saRNA appear more stable at refrigerated or even room temperatures, reducing reliance on ultra-cold storage that has challenged global COVID-19 vaccine distribution.

Applications: Veterinary medicine is already testing saRNA vaccines for livestock, and human preclinical studies are targeting **influenza, HIV, and oncology**.

Challenges: saRNA is larger in size (~9–12 kb vs. ~2–3 kb for standard mRNA), making synthesis and delivery more complex. The replicase may also increase **innate immune recognition and reactogenicity**, requiring optimized lipid nanoparticles (LNPs) or modified nucleosides to reduce inflammation.

In essence, saRNA promises to deliver **more immunity with less material**, but its **translation into late-phase human trials** is still limited compared to conventional mRNA.

Circular RNA (circRNA):

Circular RNA (circRNA) vaccines are a newer innovation that overcome one of mRNA's major limitations: **instability**. Conventional mRNA has exposed ends (5′ cap and 3′ tail) that are prone to degradation by exonucleases. CircRNA, by contrast, is a **covalently closed loop**, with no free ends, making it significantly more resistant to enzymatic degradation.

Extended expression: circRNA can persist longer inside cells, producing antigen for an extended period. This longer antigen presentation may be key for diseases where strong **T-cell responses** and durable memory are required.

Reduced innate activation: Because circRNA lacks a cap structure and poly(A) tail, it may avoid some of the **innate immune sensors** that trigger inflammation with linear mRNA. This could improve tolerability.

Applications: Preclinical studies have shown circRNA cancer vaccines can generate **strong $CD8^+$ T-cell responses** and tumor regression in mouse models. Infectious disease applications are emerging for influenza and coronaviruses.

Limitations: circRNA translation efficiency is often lower than capped mRNA. To overcome this, circRNA constructs include **internal ribosome entry sites (IRES)** or engineered translation enhancers. Manufacturing at scale is also more complex and not yet standardized under GMP conditions.

CircRNA represents a potential **"third generation" RNA vaccine platform**, combining stability, durability, and lower reactogenicity—but it remains at the preclinical and very early clinical stage.

Multivalent and Multistage Designs:

While saRNA and circRNA improve the **platform backbone**, multivalent and multistage strategies optimize **antigen breadth and design**.

Multivalent infectious disease vaccines:

Influenza: Candidates like Moderna's **mRNA-1010** or broader "pan-influenza" constructs combine multiple hemagglutinin antigens to cover both seasonal drift and potential pandemic strains.

Cytomegalovirus (CMV): Moderna's **mRNA-1647** encodes **six viral proteins** (including pentameric complex and glycoprotein B) to induce both neutralizing antibodies and T-cell responses. This multivalent strategy aims to prevent congenital CMV, a challenge unmet by single-antigen vaccines.

Multistage vaccines for complex pathogens:

For diseases like **malaria**, vaccines need to target more than one stage of the parasite lifecycle (sporozoite in the liver, merozoite in blood). Multistage mRNA constructs could combine these targets in a single vaccine, improving efficacy.

Oncology applications:

Personalized cancer vaccines are inherently multivalent. Each patient's tumor mutational profile can generate **10–20 unique neoantigens**, all encoded in one modular mRNA construct. This **bespoke approach** is feasible only because of the **flexibility of mRNA synthesis pipelines**.

Key challenges with multivalent/multistage approaches include balancing expression between antigens (to avoid dominance of one response), ensuring correct protein folding for complex viral antigens, and managing **regulatory approval pathways** for highly complex constructs.

Synthesis:

Taken together, **saRNA, circRNA, and multivalent/multistage design strategies** represent the next wave of RNA vaccine innovation:

saRNA addresses the challenge of **dose efficiency** and **manufacturing scalability**.

circRNA addresses **stability** and **durability of immune responses**.

Multivalent/multistage designs address **pathogen complexity** and **oncology personalization**.

These innovations complement each other, and in the coming decade we may see **hybrid vaccines**—for example, a **saRNA circRNA construct encoding multiple antigens**—that combine their strengths to expand the reach of RNA technology to **persistent viruses, parasites, and cancer**.

Delivery, Formulation & Routes in Next-Generation mRNA Vaccines:

Next-Generation Lipid Nanoparticles (LNPs):

Lipid nanoparticles (LNPs) remain the gold standard for delivering mRNA, providing protection against nuclease degradation, facilitating cellular uptake, and enabling cytoplasmic release. However, **first-generation LNPs**, as used in COVID-19 vaccines, had limitations: they often induced systemic reactogenicity, showed preferential hepatic biodistribution, and required ultracold storage. To address these issues, **next-generation LNPs** are being engineered with **ionizable lipids tuned for endosomal escape**, improving both transfection efficiency and tolerability. These lipids are pH-sensitive, carrying a neutral charge at physiological pH but becoming positively charged in the acidic endosome, thus promoting endosomal rupture and RNA release. Recent studies (RSC Publishing, ScienceDirect) describe **lipid–polymer hybrid nanoparticles**, which integrate synthetic polymers with lipid shells to enhance stability, allow **targeted organ delivery**, and modulate immune activation. Researchers are also investigating **tissue-specific formulations** (e.g., lung-targeting LNPs for respiratory pathogens or spleen-targeting LNPs for immune training). These advances broaden the clinical utility of mRNA vaccines beyond systemic prophylaxis, paving the way for **precision immunization strategies**.

Thermostability & Logistics:

One of the greatest bottlenecks in global mRNA vaccine distribution has been the **stringent cold-chain requirements** (–20 °C to –70 °C). This severely limited deployment in **low- and middle-income countries (LMICs)**. To address this, researchers are working on **lyophilization (freeze-drying) techniques** and **excipient optimization** to improve thermostability. Lyophilized mRNA-LNP formulations can potentially be stored at **2–8 °C** for extended periods, while some experimental formulations remain stable even at room temperature for weeks. Excipients such as sugars (trehalose, sucrose) and polymers are being tested to stabilize the LNP structure and prevent aggregation during drying and rehydration. Comparative studies are ongoing to evaluate **immunogenic equivalence** between lyophilized and liquid formulations, with early results showing minimal loss of potency. These developments are not just logistical but **equity-driven**: improving thermostability will reduce vaccine wastage, simplify transportation, and enable **rapid deployment in pandemic settings**, particularly in regions with fragile infrastructure.

Alternate Routes of Administration:

While most current mRNA vaccines are given intramuscularly, researchers are actively exploring **alternate administration routes** that could enhance efficacy, reduce dosage, or improve accessibility.

Intradermal delivery: The dermis is rich in antigen-presenting cells, making it an attractive site for immune priming. Studies suggest that intradermal mRNA administration can achieve similar immune responses at **lower doses** than intramuscular injection, supporting **dose-sparing strategies** in resource-limited settings.

Mucosal delivery: For respiratory pathogens such as influenza, RSV, or coronaviruses, mucosal immunity (particularly IgA and tissue-resident T cells) is crucial. Preclinical work on **intranasal and inhalable mRNA-LNP formulations** has shown the potential to induce strong local mucosal immunity alongside systemic responses. However, challenges include ensuring **efficient uptake across mucosal barriers**, maintaining RNA stability in the presence of mucus enzymes, and avoiding excessive local inflammation.

Other routes under evaluation: Subcutaneous injections, microneedle patches, and even oral capsules with protective coatings are being investigated. Microneedle patches are especially promising for **self-administration**, enabling wide distribution without the need for trained healthcare workers.

Synthesis:

Delivery innovations are central to the **next era of mRNA vaccines**. Next-gen LNPs expand the spectrum of targetable organs and reduce side effects, **thermostability breakthroughs** remove cold-chain barriers, and **alternate routes** open doors to dose-sparing and mucosal protection. Together, these advances address the two most pressing needs in RNA vaccinology: **scientific performance** (stronger, broader, safer immunity) and **global accessibility** (affordable, logistically feasible deployment).

Manufacturing, Regulation & Access in mRNA Vaccines:

From Pandemic Scale-Up to Routine Supply:

The COVID-19 crisis demonstrated the **scalability and speed of mRNA manufacturing** but also exposed vulnerabilities. Production was scaled almost overnight by leveraging **in vitro transcription (IVT) reactions**, which synthesize RNA from DNA templates using enzymes and nucleotide triphosphates. Unlike protein-based vaccines that require cell culture and fermentation, mRNA

vaccines can be produced in a **cell-free system**, allowing faster scale-up. However, this approach depends on **nucleoside triphosphate (NTP) supply chains, capping reagents, and lipid precursors**, which became global bottlenecks during the pandemic.

To overcome this, industry leaders are moving toward **distributed manufacturing models** with **modular, single-use facilities**. These are compact units with **disposable bioreactors, filters, and chromatography columns**, which reduce cleaning/validation time and allow flexible production switching between vaccines. For quality, **digital QC pipelines** now integrate real-time assays such as capillary electrophoresis for RNA integrity and nanoparticle tracking for LNP size distribution. This compresses **batch release from weeks to days**.

A major shift is also underway toward **regional tech-transfer hubs**, supported by WHO and CEPI, which train scientists in LMICs to operate mRNA facilities. For example, South Africa's Afrigen Biologics is working to develop a homegrown mRNA vaccine manufacturing capability. These initiatives are essential to prevent **repeat inequities** in access, as seen with COVID-19 where low-income countries received vaccines months later than high-income nations.

Regulatory Science:

mRNA vaccines are a novel modality, and regulators had to **adapt frameworks in real time** during COVID-19. The FDA and EMA developed **emergency pathways** for rapid review, relying on surrogate endpoints such as neutralizing antibody titers instead of years-long efficacy trials. This set a precedent: moving forward, regulators are expected to treat **variant-updated mRNA vaccines** similarly to flu strain updates, requiring **bridging immunogenicity studies** rather than full-scale phase 3 efficacy trials.

The challenge now is how to apply these standards to **latent and complex infections**. For CMV and EBV, no validated correlates of protection exist. Regulators must decide whether to rely on composite endpoints (e.g., viral shedding, maternal-to-fetal transmission rates, T-cell functionality) or mandate long-term clinical outcomes. Combination vaccines—such as **COVID + influenza boosters**—also require careful evaluation of **antigenic interference** (where immune responses to one component might dominate or suppress another).

Safety regulation is another frontier. LNPs can trigger innate immune responses, and rare side effects such as myocarditis raised concerns during COVID-19. Regulators are therefore emphasizing **post-marketing pharmacovigilance systems**, including active surveillance with electronic health records and global adverse event reporting networks. Companies like **Moderna** have stressed that **early dialogue with regulators** is critical to align trial endpoints, comparability standards, and long-term safety monitoring before expanding indications.

Personalized Vaccines at Scale:

Personalized mRNA cancer vaccines represent a **paradigm shift** in immunotherapy but face enormous manufacturing and regulatory hurdles. The workflow typically involves:

Tumor sequencing (DNA & RNA): Identifying mutations and expression levels.

Neoantigen prediction: Using AI-driven algorithms to rank which mutations are most likely to bind HLA molecules and be recognized by T cells.

Vaccine design: Selecting 10–20 top-ranked epitopes, designing codon-optimized mRNA constructs, and incorporating them into a modular LNP formulation.

Manufacturing under cGMP: Each patient-specific batch must be synthesized, purified, encapsulated, and tested for sterility and potency.

Clinical release: Regulatory approval for injection within 6–8 weeks of tumor biopsy.

This workflow is currently expensive (often exceeding **$100,000 per patient**) and time-sensitive. The bottlenecks are:

Bioinformatics: Algorithms are not always accurate in predicting which mutations will generate strong T-cell responses. This can lead to wasted resources on non-immunogenic targets.

cGMP capacity: Existing facilities are optimized for bulk production, not individualized lots. This requires **miniaturized, automated RNA printers** that can rapidly make bespoke vaccines.

Regulatory testing: Current QC standards were designed for large-scale vaccines, not single-patient batches. Regulators are exploring **adaptive release protocols**, where validated automated platforms could reduce redundant testing.

If solved, personalized mRNA vaccines could become part of **routine cancer care**, delivered alongside checkpoint inhibitors or other immunotherapies. However, without breakthroughs in automation and cost reduction, they risk being confined to elite cancer centers in wealthy countries.

Synthesis:

The future of mRNA vaccines will depend as much on **manufacturing, regulation, and equitable access** as on scientific breakthroughs. The **pandemic response model** proved that mRNA is fast and flexible, but to sustain this in routine immunization, the world must:

Decentralize production through modular facilities and regional hubs.

Modernize regulation, allowing rapid approvals for variant updates and combination vaccines while setting new standards for latent-virus candidates.

Automate personalized manufacturing, reducing turnaround times and costs to make bespoke cancer vaccines accessible beyond niche markets.

Ultimately, mRNA technology will only fulfill its promise if innovations in **science, production, and governance** evolve together, ensuring that both **seasonal vaccines** and **personalized therapies** are safe, affordable, and globally available.

Open Challenges & Future Directions:

Durability & Breadth:

A central challenge for next-gen mRNA vaccines is to elicit **long-lived, breadth-oriented immunity**—across antigenic drift (influenza), diverse genotypes (HIV, HCV), and immune-evasive tumors.

Mechanistic levers for durability (B-cell & T-cell):

Germinal center (GC) longevity: Prolonged GC reactions favor higher-affinity, class-switched antibodies and memory formation. With mRNA, this can be tuned by: (i) **dose fractionation** (prime with a moderate dose; boost after GC contraction), (ii) **extended prime-boost intervals** (e.g., ≥8–12

weeks), and (iii) **slow-release depots** (e.g., lyophilized or polymer-hybrid LNPs) to maintain antigen availability.

Tfh help & CD4 breadth: Robust **T follicular helper (Tfh)** responses correlate with durable humoral immunity. Options include encoding **CD4 helper epitopes** within the mRNA cassette, or co-formulating adjuvant motifs (see below) that bias toward Tfh differentiation.

Memory T-cell quality: For pathogens and cancer, polyfunctional **CD8**$^{+}$ and **tissue-resident** T cells (TRM) predict protection. Route changes (e.g., **intradermal** for dose-sparing and **mucosal** boosters for TRM) can improve localization and longevity.

Engineering "adjuvanting" within mRNA/LNP:

Sequence-level tuning: UTRs, codon usage, and ORF architecture modulate translation kinetics, which in turn shapes antigen persistence.

Innate-sensing balance: Nucleoside modifications (e.g., m$^{1}\Psi$) reduce excessive innate activation to avoid blunting translation, while **ionizable lipids** provide a built-in adjuvant effect. Emerging strategies add **TLR7/8 or STING agonists** in trace amounts or encode cytokines/chemokines (e.g., IL-12, CXCL13) to steer Tfh and CTL help—cautiously, to avoid reactogenicity.

Mitigating immune imprinting (original antigenic sin):

Antigen design for breadth: Use **mosaic/multivalent immunogens** that weight conserved regions; in influenza, chimeric HA or "stem-focused" constructs reduce head-domain recall. In HIV/HCV, **germline-targeting primes** can be followed by **epitope-scaffold boosts** to shepherd maturation toward broadly neutralizing sites.

Schedule strategy: Delayed or **heterologous boosts** (e.g., mRNA → protein nanoparticle) can reshape memory B-cell competition and broaden clonotype recruitment.

Mucosal re-focusing: Intranasal or inhaled boosts promote **IgA** and TRM at portals of entry, reducing recall bias from systemic IgG-dominated memory.

Durability endpoints & analytics: Prioritize **memory B-cell ELISpot**, **serum/secretory IgA**, **Tfh signatures**, **TRM phenotyping**, and **breadth metrics** (antigenic cartography for viruses; neoantigen spread in oncology) alongside neutralization titers.

Discovery Frontier

Extending RNA vaccinology to **persistent viruses** (HIV, HCV, HBV), **complex parasites** (malaria), **intracellular bacteria** (TB), and **solid tumors** will hinge on platform and delivery breakthroughs:

Platforms:

saRNA (self-amplifying RNA): lowers dose by intracellular replication—promising for **mass deployment and stockpiling**, provided reactogenicity is tuned and payload size constraints are addressed.

circRNA: covalently closed loops yield **longer expression windows** with potentially lower innate activation—attractive for **T-cell-heavy indications** (HIV, cancer), pending scalable GMP workflows.

Multi-payload strategies: Single vials encoding **poly-antigen panels** (e.g., CMV's multi-protein vaccine; malaria's liver + blood stage) or **personalized tumor neoantigen sets** (10–20 epitopes) via modular assembly.

Adjuvanting & delivery:

Next-gen LNP targeting: Lymph-node–tropic particles to bias antigen presentation; lung-tropic aerosols for respiratory pathogens; **microneedle patches** for painless, self-administered boosters.

Thermostability: Lyophilized LNPs with sugar glass matrices (trehalose/sucrose) and excipient cocktails to enable **2–8 °C storage** or short-term room-temperature resilience—critical for LMIC rollout.

Combination modalities: mRNA co-formulated with **protein nanoparticles** or **viral vectors** in staged regimens (prime/boost) to orchestrate BNAb maturation (HIV) or multi-arm cellular immunity (malaria/TB).

Indication-specific blueprints:

HIV: Germline-targeting **primers** → sequential **epitope-focused boosters** that present increasingly native-like Env features; include lineage-tracking to verify on-pathway maturation toward bnAbs.

HCV: Emphasize **T-cell vaccines** (NS3/NS5 epitopes) plus antibody components for entry factors (E1/E2); assess sterilizing vs functional cure endpoints with DAA backstops.

Malaria: Multistage (CSP/TRAP + blood-stage antigens) with **mucosal or intradermal** boosts; evaluate **sporozoite challenge** correlates and durability across seasons.

Oncology: Faster **AI-driven neoantigen selection**, shared "public" neoantigens to lower cost, and **in situ** vaccination concepts (mRNA encoding cytokines/chemokines) to remodel cold tumors.

Risk–Benefit & Equity Lens:

Safety/reactogenicity: Maintain transparency on myocarditis, neurologic AEs, and rare hypersensitivity; expand **active pharmacovigilance** and mechanistic studies (lipid chemistry, dose density).

Access & affordability: Pair scientific advances with **regional tech-transfer hubs**, harmonized **variant-update pathways**, and **thermostable presentations** to shrink the delivery gap in LMICs.

Manufacturing sustainability: Distributed, **single-use modular plants** and automated QC (rapid release) are prerequisites for seasonal combo shots and bespoke oncology lots.

A Focused Research Agenda (actionable next steps):

Durability trials: Randomize **intervals and doses** to map GC kinetics; co-measure Tfh, TRM, memory B-cell breadth, and waning curves over **24+ months**.

Imprinting mitigation: Head-to-head comparisons of **mosaic vs monovalent** antigens and **mucosal vs IM** boosts; quantify breadth with deep BCR sequencing and antigenic maps.

saRNA/circRNA head-to-heads: Standardized, blinded comparisons of **expression kinetics, reactogenicity, and breadth** with identical antigens in animals → phase-1 translation.

Thermostability toolkits: Open-access SOPs for **lyophilization** and **reconstitution**; stability-indicating assays and field studies at **2–8 °C** in LMIC settings.

Targeted delivery: Preclinical **lymph-node–tropic** and **lung-tropic** LNP libraries with biodistribution + single-cell immune readouts; translate winners to FIH studies.


HIV/HCV/malaria roadmaps: Pre-agreed **stage-gated regimens** (germline primes → focusing boosts for HIV; T-cell–dominant for HCV; multistage for malaria) with shared data standards.

Oncology scale-up: Validate **automated neoantigen pipelines**, mini-GMP "RNA printers," and **adaptive QC** for rapid patient-specific lot release; measure cost/time per dose.

Global equity: Fund **regional manufacturing hubs**, pooled procurement for lipids/enzymes, and **regulatory harmonization** for variant and combination products.

Bottom line:

Achieving **durable, broad, and equitable** protection is the next frontier. The winners will be platforms and programs that **optimize antigen design + dosing schedules**, **balance innate sensing for Tfh/CTL help**, and **solve delivery/logistics** (thermostability, targeted LNPs, mucosal routes). If saRNA, circRNA, and precision adjuvanting deliver on their promise—and manufacturing/regulatory innovations keep pace—mRNA vaccines can expand from seasonal respiratory use into **HIV/HCV, malaria, TB, and routine oncology care** over the coming decade.



Summary:

mRNA vaccines have decisively moved **beyond COVID-19**. The first non-COVID approval (RSV) and **positive phase-3 influenza data** point to near-term routine respiratory indications, while **CMV** and **norovirus** programs progress for public-health impact. In oncology, **personalized mRNA vaccines** combined with checkpoint inhibitors are reshaping adjuvant paradigms, with encouraging signals even in hard-to-treat tumors. Next-generation **saRNA** and **circRNA** promise dose-sparing and longer expression, and improvements in **LNP chemistry** plus thermostabilization will expand reach and cut costs. The remaining hurdles are scientific (durability, breadth), operational (manufacturing at scale, QC), and societal (equity, confidence). With sustained innovation and rigorous evaluation, mRNA platforms are poised to become a backbone of both **prophylactic immunization** and **cancer therapy** in the coming decade.

References:

CIDRAP. Moderna receives expanded approval for RSV vaccine (mRESVIA; mRNA-1345). 2025.

Pharmacy Times. FDA Approves mRNA-1345 Vaccine for Adults Aged 18–59 Years. 2025.

Reuters. Moderna's experimental flu vaccine more effective than approved shot in study (mRNA-1010, phase 3). 2025.

CIDRAP. Moderna announces promising efficacy results from mRNA flu vaccine trial. 2025.

Weber JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) + pembrolizumab in resected melanoma. **NEJM** (PubMed 38246194), 2024.

Merck/Moderna. KEYNOTE-942: V940 + pembrolizumab improved DMFS. Press release, 2023.

Sethna Z, et al. RNA neoantigen vaccines prime long-lived $CD8^+$ T cells in PDAC. **Nature**, 2025.

Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. **Nature**, 2023.

ClinicalTrials.gov. NCT05085366 — Phase 3 CMV vaccine mRNA-1647. Record history updated 2025.

Moderna. Product pipeline (HIV mRNA-1644; norovirus, EBV, HSV, VZV, etc.). 2025.

IAVI. Two HIV vaccine trials show proof of concept for pathway to bnAbs (G002/G003). 2025.

ClinicalTrials.gov. NCT05001373 — First-in-human eOD-GT8 60mer mRNA vaccine (mRNA-1644).

Niu D, et al. Circular RNA vaccine in disease prevention and treatment. **Signal Transduct Target Ther**, 2023.

Voigt EA, et al. A self-amplifying RNA vaccine with long shelf life. **NPJ Vaccines**, 2022.

Wang T, et al. Next-generation materials for RNA–lipid nanoparticles. **J. Mater. Chem. B**, 2023.

Buitrago-Pabón AL, et al. An update on Zika virus vaccine development. **TropMed Infect Dis**, 2024.

Parks KR, et al. mRNA-encoded membrane-anchored HIV Env trimers elicit tier-2 nAbs (phase 1). **Sci Transl Med**, 2025.

Essink B, et al. Safety and immunogenicity of Zika mRNA vaccines (mRNA-1325, mRNA-1893) — phase 1. **Lancet Infect Dis**, 2023.

Bollman B, et al. Optimized mRNA Zika vaccine protects non-human primates. **NPJ Vaccines**, 2023.

Sofroniou A, et al. Systematic review of clinical trials using mRNA technology (post-COVID landscape). **Vaccines**, 2025.